Daré Bioscience (NASDAQ:DARE – Get Free Report) and Pasithea Therapeutics (NASDAQ:KTTA – Get Free Report) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, dividends, profitability, analyst recommendations, valuation, risk and institutional ownership.
Institutional & Insider Ownership
6.7% of Daré Bioscience shares are held by institutional investors. Comparatively, 23.9% of Pasithea Therapeutics shares are held by institutional investors. 4.0% of Daré Bioscience shares are held by insiders. Comparatively, 16.3% of Pasithea Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
Profitability
This table compares Daré Bioscience and Pasithea Therapeutics’ net margins, return on equity and return on assets.
Net Margins | Return on Equity | Return on Assets | |
Daré Bioscience | -191.65% | N/A | -18.68% |
Pasithea Therapeutics | N/A | -81.57% | -74.31% |
Analyst Recommendations
Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
Daré Bioscience | 0 | 2 | 2 | 0 | 2.50 |
Pasithea Therapeutics | 0 | 0 | 0 | 0 | 0.00 |
Daré Bioscience currently has a consensus price target of $24.00, indicating a potential upside of 650.00%. Given Daré Bioscience’s stronger consensus rating and higher possible upside, analysts clearly believe Daré Bioscience is more favorable than Pasithea Therapeutics.
Volatility and Risk
Daré Bioscience has a beta of 1.34, suggesting that its stock price is 34% more volatile than the S&P 500. Comparatively, Pasithea Therapeutics has a beta of 0.82, suggesting that its stock price is 18% less volatile than the S&P 500.
Valuation & Earnings
This table compares Daré Bioscience and Pasithea Therapeutics”s top-line revenue, earnings per share (EPS) and valuation.
Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
Daré Bioscience | $2.84 million | 9.63 | -$30.16 million | ($0.59) | -5.42 |
Pasithea Therapeutics | $20,000.00 | 203.20 | -$15.96 million | N/A | N/A |
Pasithea Therapeutics has lower revenue, but higher earnings than Daré Bioscience.
Summary
Daré Bioscience beats Pasithea Therapeutics on 7 of the 12 factors compared between the two stocks.
About Daré Bioscience
Daré Bioscience, Inc., a biopharmaceutical company, identifies, develops, and markets products for women's health in the United States. It develops therapies in the areas of contraception, reproductive health, menopause, fertility, and sexual and vaginal health. The company offers XACIATO for the treatment of bacterial vaginosis in female patients 12 years of age and older. It is developing Ovaprene, a hormone-free, monthly intravaginal contraceptive; Sildenafil Cream, a cream formulation of sildenafil for topical administration to the female genitalia on demand for the treatment of female sexual arousal disorder; DARE-HRT1 to treat moderate to-severe vasomotor symptoms in menopausal hormone therapy; DARE-VVA1 for the treatment of moderate-to-severe dyspareunia or pain during sexual intercourse; and DARE-CIN to treat cervical intraepithelial neoplasia and other human papillomavirus related pathologies. The company is also developing DARE-PDM1 for the treatment of primary dysmenorrhea; DARE-204 and DARE-214, an injectable formulations contraception of etonogestrel designed to provide contraception over 6-month and 12-month periods; DARE-FRT1, an intravaginal ring designed to deliver bio-identical progesterone for luteal phase support as part of an in vitro fertilization treatment plan; and DARE-PTB1 for the prevention of preterm birth. In addition, it is developing DARE-LARC1, a contraceptive implant delivering levonorgestrel with a woman-centered design that controlled contraceptive option; DARE-LBT, a novel hydrogel formulation for vaginal delivery of live biotherapeutics to support vaginal health; DARE-GML, a multi-target antimicrobial agent; DARE-RH1, a novel approach to non-hormonal contraception for men and women by targeting the CatSper ion channel; and DARE-PTB2 for the prevention and treatment of idiopathic preterm birth through inhibition of a stress response protein. Daré Bioscience, Inc. is headquartered in San Diego, California.
About Pasithea Therapeutics
Pasithea Therapeutics Corp., a biotechnology company, engages in discovery, research, and development of treatments for central nervous system disorders, RASopathies, and other diseases. Its lead product candidate PAS-004, a next-generation macrocyclic mitogen-activated protein kinase, or MEK inhibitor for use in the treatment of a range of RASopathies, including neurofibromatosis type 1 oncology indications. The company intends to develop PAS-003, to treat amyotrophic lateral sclerosis; and PAS-001, to treat schizophrenia. Pasithea Therapeutics Corp. was incorporated in 2020 and is headquartered in Miami Beach, Florida.
Receive News & Ratings for Daré Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Daré Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.